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KEY POINTS 
-)LEULQRJHQȖ-chain residues 390-396 bind FXIII-A2B2 and mediate its activation in a FXIII-B 
subunit-dependent mechanism. 
-Excess FXIII-B2 in plasma circulates bound to fibrinogen. 
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ABSTRACT 
The coagulation transglutaminase factor XIII (FXIII) exists in circulation as the heterotetrameric 
proenzyme FXIII-A2B2. Effectively all FXIII-A2B2 circulates bound to fibrinogen, and excess 
FXIII-B2 circulates in plasma. The motifs that mediate interaction of FXIII-A2B2 with fibrinogen 
have been elusive. We recently detected reduced binding of FXIII-A2B2 to murine fibrinogen 
WKDWKDVȖ-chain residues 390-PXWDWHGWRDODQLQHV)LEȖ390-396A). Here, we evaluated binding 
features using human components, including recombinant fibrinogen variants, FXIII-A2B2, and 
isolated FXIII-A2 and -B2 homodimers. FXIII-A2B2 co-precipitated with wild-W\SHȖ$Ȗ$
alternatively-VSOLFHGȖމȖމDQGĮ&-WUXQFDWHG$ĮILEULQRJHQVZKHUHDVFR-precipitation with 
KXPDQ)LEȖ390-396A was reduced by 75% (P<0.0001). 6XUIDFHSODVPRQUHVRQDQFHVKRZHGȖ$Ȗ$
ȖމȖމDQG$Įfibrinogens bound FXIII-A2B2 with high affinity (nM); however, )LEȖ390-396A 
did not bind FXIII-A2B2. These data indicate fibrinogen residues Ȗ390-396 comprise the major 
binding motif for FXIII-A2B2. &RPSDUHGWRȖ$Ȗ$FORWV);,,,-A2B2 activation peptide release 
was 2.7-fold slower in )LEȖ390-396A clots (P<0.02). Conversely, activation of recombinant FXIII-
A2 (lacking FXIII-B2) was similar LQȖ$Ȗ$DQG)LEȖ390-396A clots, suggesting fibrinogen residues 
Ȗ-396 accelerate FXIII-A2B2 activation in a FXIII-B2-dependent mechanism. Recombinant 
FXIII-B2 ERXQGȖ$Ȗ$ȖމȖމDQG$ĮZLWKVLPLODUDIILQLWLHVDV);,,,-A2B2, but did not bind 
or co-SUHFLSLWDWHZLWK)LEȖ390-396A. FXIII-B2 also co-precipitated with fibrinogen in plasma from 
F13a -/- mice. Collectively, these data indicate that FXIII-A2B2 ELQGVILEULQRJHQUHVLGXHVȖ-
396 via the B subunits, and that excess plasma FXIII-B2 is not free, but rather, circulates bound 
to fibrinogen. These findings provide insight into assembly of the fibrinogen/FXIII-A2B2 
complex in both physiologic and therapeutic situations.  
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INTRODUCTION 
 Factor XIII (FXIII) is a plasma protransglutaminase that circulates at 14-28 µg/mL (43-86 
nM, reviewed in 1). Zymogen FXIII is composed of two A subunits (FXIII-A2) and two carrier B 
subunits (FXIII-B2) assembled as a non-covalent heterotetramer (FXIII-A2B2). In plasma, FXIII-
A2 is tightly-associated (KD ~100 pM)2 with FXIII-B2. Excess FXIII-B2 (43-62 nM) is present in 
circulation.2,3 During coagulation, FXIII-A2B2 is activated by thrombin-mediated cleavage of an 
N-terminal, 37-amino acid activation peptide from the FXIII-A subunits (FXIII-A2މ). After 
activation peptide release, calcium promotes the dissociation of the inhibitory FXIII-B subunits, 
yielding fully activated FXIII-A2* ();,,,D2QFHDFWLYDWHG);,,,DFDWDO\]HVWKHIRUPDWLRQRIİ-
N-Ȗ-glutamyl)-O\V\OFURVVOLQNVEHWZHHQȖ- DQGĮ-chains of fibrin and between fibrin and other 
plasma proteins. Crosslinking is essential for clot mechanical and biochemical stability 
(reviewed in 1). )LEULQĮ-chain crosslinking also promotes red blood cell retention in venous 
thrombi and consequently, mediates thrombus composition and size.4,5 
 FXIII-A2B2 circulates in complex with fibrinogen (KD ~10 nM)6, and these proteins are 
readily co-precipitated from plasma.7 However, the fibrinogen residues that mediate binding to 
FXIII-A2B2 in humans have not been defined. Early studies suggested the alternatively-spliced 
ILEULQRJHQȖމ-chain contained the FXIII-A2B2 binding site.8,9 However, studies using recombinant 
fibrinogen showed that FXIII-A2B2 ELQGVWRȖ- DQGȖމ-containing fibrinogen with similar 
affinity10VXJJHVWLQJWKHȖމ-extension is not necessary for FXIII-A2B2 binding. More recently, 
Smith et al. observed high affinity binding of non-activated FXIII-A2B2 to a glutathione-S-
transferase-fused peptide containing amino acid residues 371-RIWKHILEULQRJHQĮ&GRPDLQ.11 
However, whether WKHILEULQRJHQĮ&GRPDLQ fulfills the carrier function of FXIII-A2B2 remains 
unclear.  
 We recently observed decreased co-precipitation of FXIII-A2B2 with murine fibrinogen that 
has alanine substitutions ZLWKLQUHVLGXHVȖ-396 (NRLSIGE to AAAAAAA)LEȖ390-396A), 
suggesting WKHVHȖ-chain residues mediate the FXIII-A2B2 carrier function in mice.4 Accordingly, 
Souri et al. subsequently detected binding of FXIII-A2B2 to the human fibrinogen Ȗ-chain at 
residues C-WHUPLQDORIȖLys356.12 Notably, fibrinogen residues Ȗ390-396 are highly conserved in 
mammals (NRLTIGE [human, gorilla, dog], NRLSIGD [rat], and NRLAIGE [giant panda]), 
suggesting these residues fulfill this essential, conserved function across species.  
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 Herein, we used entirely human components, including recombinant human fibrinogen 
variants and human FXIII heterotetramers and homodimers, as well as FXIII-deficient mice, to 
define the interaction between these proteins. Our data reveal a direct interaction between human 
ILEULQRJHQUHVLGXHVȖ-396 and the FXIII-B subunits, and uncover a fundamental mechanism 
mediating FXIII-fibrinogen complex assembly in blood. These data have important implications 
for both physiologic assembly of this complex in healthy individuals, and assembly in FXIII-A2-
deficient patients receiving therapeutic recombinant FXIII-A2. 
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METHODS 
Proteins and Materials. Anti-human fibrinogen antibody was from Dako (Carpinteria, CA) and 
AlexaFluor 488 anti-rabbit and anti-sheep secondary antibodies were from Jackson 
Immunoresearch (West Grove, PA). Two rabbit polyclonal anti-FXIII-B antibodies were used: 
HPA003827 (Sigma Aldrich, St. Louis, MO) and A074 (Zedira, Darmstadt, Germany), as 
indicated. Plasma FXIII-A2B2, anti-human FXIII-A antibody, and peak 1 human fibrinogen 
(FXIII-depleted) were from Enzyme Research Laboratories (ERL, South Bend, IN). 
Recombinant FXIII-A2 (rFXIII-A2) was a generous gift of Novo Nordisk (Bagsværd, Denmark). 
FXIII-A2B2 (plasma-derived) used for surface plasmon resonance and recombinant FXIII-B2 
(rFXIII-B2, produced in insect cells) were from Zedira. Insect cell-derived FXIII-B2 undergoes 
different post-translational modification than human plasma-derived FXIII-B2 and migrates 
slightly faster on SDS-PAGE. Murine studies were approved by the Institutional Animal Care 
DQG8VH&RPPLWWHHVRIWKH&LQFLQQDWL&KLOGUHQ¶V+RVSLWDO0HGLFDO Center and the University of 
North Carolina at Chapel Hill. Additional materials and sources are detailed in the Supplemental 
Materials.  
 
Expression of recombinant fibrinogen variants. A vector H[SUHVVLQJUHFRPELQDQW)LEȖ390-396A 
was constructed as detailed in Supplemental Materials. Recombinant human wild-W\SHȖ$Ȗ$ 
alternatively-spliced (ȖމȖމ), Į&-truncated ($Į), and )LEȖ390-396A )LEȖ390-396A) fibrinogen 
variants were expressed in Chinese Hamster Ovary cells and affinity-purified as previously 
described.13-15 
 
Fibrinogen precipitation experiments. Fibrinogen (1 mg/mL >ȝ0@, final) was incubated 
with FXIII-A2B2 ȝJP/ [60 nM], final), rFXIII-A2 ȝJP/ [60 nM], final), or rFXIII-B2 
ȝJP/ [63 nM], final) at room temperature for 15 minutes. Glycine (165 mg/mL) was then 
added and samples were rotated for 1 hour, after which the precipitate was pelleted by 
centrifugation (7000xg, 15 minutes) and resuspended in HEPES-buffered saline (HBS; 20 mM 
HEPES [pH 7.4], 150 mM NaCl). Fibrinogen, FXIII-A, and FXIII-B content of the initial 
sample, pellet, and supernatant were assessed by Western blotting under reducing conditions, 
unless otherwise specified. Briefly, samples were separated by SDS-PAGE on 10% Tris-Glycine 
gels, transferred to polyvinylidene fluoride membranes, and probed with primary antibodies 
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(rabbit anti-human fibrinogen [1:7000], sheep anti-human FXIII-A [1:1000], or rabbit anti-
human FXIII-B [HPA003827, 1:500]) overnight at 4°C before incubation with fluorescently-
labeled secondary antibodies for 1 hour at room temperature. Blots were visualized using a 
Typhoon FLA9000 Imager (GE Healthcare, Little Chalfont, UK). Densitometry was performed 
with ImageJ 1.48v. Percentage of FXIII-A or FXIII-B in the pellet was determined by dividing 
the intensity of the subunit band in the pellet by the sum of the band intensities in both the pellet 
and the supernatant. 
 For experiments with mouse plasma, blood was drawn via the inferior vena cava and 
processed to platelet-poor plasma by centrifugation (5000xg, 10 minutes). Fibrinogen was 
isolated from wild-type (F13a+ /+), heterozygous (F13a+/-), FXIII-deficient (F13a-/-)4,16, or 
afibrinogenemic17 mouse plasma by glycine precipitation4. For experiments with 
immunodepleted human plasma (Affinity Biologicals, Ancaster, ON, lacks both FXIII-A and 
FXIII-B), plasma was first reconstituted with 20 ȝJP/U);,,,-B2 prior to glycine precipitation. 
Precipitated fibrinogen and FXIII-A were detected as above. Both murine and human FXIII-B 
were detected using anti-human FXIII-B antibody (A074, 1:1000 overnight at room 
temperature).  
 
Surface plasmon resonance (SPR). SPR ligands and analytes were prepared as detailed in 
Supplemental Materials. SPR was performed on a SensiQ Pioneer platform described in the 
Supplemental Materials. Fibrinogen analytes were diluted to 50 nM or 1 µM using the same 
batch of running buffer for blanks and the OneStep® titration function. Fibrinogen analytes were 
injected into the sensor chamber at a flow-rate of 30 µL/min using the OneStep® titration 
function18,19 with a loop-inject of 75% following 5 leadoff blanks and 3 bulk standard injections 
of 3% sucrose in running buffer. The 50 nM and 1 µM samples had dissociation times of 500 and 
1000 seconds, respectively. The chip surface was regenerated with 2 M NaCl (30 µL/min, 60 
seconds), followed by 3 M NaCl (30 µL/min, 60 seconds).  
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 Data were analyzed with Qdat data analysis software (SensiQ Technologies Inc., Oklahoma 
City, OK). Binding data were fit using a simple ka/kd model and aggregation/retention 
parameters adjusted per binding curve according to goodness of fit and curve type. Sensorgrams 
from experiments with 50 nM fibrinogen analytes (maximum) recognized one binding site and 
were fit using a one-site model. Sensorgrams with 1 µM fibrinogen analyte (maximum) 
identified two binding sites for some FXIII ligands, so these data were fit using a two-site 
binding model; however, given the plasma concentrations of FXIII-A2B2 and fibrinogen, 
affinities for the second binding sites (0.7-21 µM) were considered too weak to be 
physiologically-relevant. Thus, only data from the first, high-affinity site are reported. 
 
FXIII activation and fibrin crosslinking. FXIII-A2B2 ȝJP/ [60 nM], final) or rFXIII-A2 
ȝJP/ [60 nM], final) were incubated with fibrinogen (0.15 mg/mL [440 nM], final) at room 
temperature for 15 minutes. Reactions were triggered with thrombin (2 nM, final) and calcium 
(10 mM, final). This thrombin concentration enabled us to visualize early FXIII activation and 
fibrin crosslinking. Reactions were quenched and clots dissolved with 50 mM dithiothreitol/12.5 
mM EDTA in 8 M urea (60°C, 1 hour). Samples were boiled in SDS-containing sample buffer 
and separated using SDS-PAGE on 10% Tris-glycine gels before transfer to polyvinylidene 
fluoride membranes. Membranes were probed with primary antibodies (sheep anti-human FXIII-
A [1:1000] or rabbit anti-human fibrinogen [1:7000]; overnight, 4°C) before incubation with 
fluorescently-labeled secondary antibodies (1 hour, room temperature). Blots were visualized 
using a Typhoon FLA9000 Imager. Densitometry was performed with ImageJ 1.48v. FXIII 
activation was determined by dividing the intensity of the FXIII-Aމ band by the sum of the 
FXIII-A and FXIII-Aމ bands to obtain % of FXIII-Aމ. Crosslinking of fibrin Ȗ-chains was 
determined as previously described.12,20 
 
Statistics. Descriptive statistics (mean, standard deviation [SD], standard error of the mean 
[SEM]) were calculated and Lilliefors test was used to assess normality. FXIII-A2 and FXIII-B2 
co-precipitation with each fibrinogen variant was compared WRȖ$Ȗ$XVLQJ$129$ZLWK
Dunnett¶V post-hoc testing (Kaleidagraph, Synergy Software, v4.5). FXIII activation and fibrin 
crosslinking rates were compared using 2-WDLOHG6WXGHQW¶Vt-tests for equal or unequal variances, 
as appropriate. P<0.05 was considered statistically significant.  
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RESULTS 
)LEULQRJHQUHVLGXHVȖ-396 mediate FXIII-A2B2 binding to soluble human fibrinogen. 
Previous studies have suggested FXIII-A2B2 binds to fibrinogen at the alternatively-spliced Ȗމ-
chain8,9, residues in the ĮC domain11, or residues in the Ȗ-chain4,12. To compare FXIII-A2B2 
binding to these regions of fibrinogen, we expressed and purified recombinant human fibrinogen 
proteins: wild-type (Ȗ$Ȗ$), alternatively-spliced (ȖމȖމ)ĮC-WUXQFDWHG$Į, DQG)LEȖ390-396A. 
As expected13-15,21, each of these fibrinogen variants contained all three chains, polymerized 
normally, and were >95% clottable (Figure 1 and data not shown). We pre-incubated these 
fibrinogen variants with FXIII-A2B2, precipitated fibrinogen with glycine, and performed SDS-
PAGE and Western blotting to identify FXIII-A2B2 present in the pellets and supernatant. FXIII-
A2B2 co-SUHFLSLWDWHGZLWKȖ$Ȗ$, ȖމȖމ, and AĮ fibrinogen constructs (Figure 1). However, 
co-precipitation of FXIII-A2B2 ZLWK)LEȖ390-396A was reduced by 75% (P<0.0001, Figure 1).  
 We also quantified binding of the fibrinogen variants to FXIII-A2B2 using SPR. Consistent 
with the co-precipitation data, Ȗ$Ȗ$ and ȖމȖމILEULQRJHQVbound FXIII-A2B2 with similar, high 
affinity (Table 1, Supplemental Figure 1). &RPSDUHGWRȖ$Ȗ$ DQGȖމȖމ fibrinogens$Į
fibrinogen binding to adherent FXIII-A2B2 was slightly reduced, consistent with the finding that 
WKHĮ&GRPDLQcontributes to FXIII-A2B2-binding function11. Regardless, given these affinity 
constants (Table 1), greater than 99% of circulating FXIII-A2B2 (plasma concentration ~43-86 
nM2,3) would bind each of these variants. Notably, FLEȖ390-396A fibrinogen did not bind FXIII-
A2B2 (Table 1, Supplemental Figure 1). Collectively, these data indicate the primary binding site 
for zymogen FXIII-A2B2 LVSUHVHQWLQȖ$Ȗ$ȖމȖމDQG$ĮILEULQRJHQVEXWDEVHQWLQ)LEȖ390-
396A fibrinogen. Together with previous findings4, these results suggest the highly-conserved 
ILEULQRJHQUHVLGXHVȖ-396 mediate binding of zymogen FXIII-A2B2 to fibrinogen in both 
mice and humans. 
 
Human fibrin(ogen) residues Ȗ-396 mediate the ability of fibrin to accelerate FXIII-
A2B2 activation. During fibrin formation, FXIII-A2B2 binding to the fibrin D:E:D/thrombin 
complex accelerates FXIII activation peptide cleavage and FXIII activation.12,22-28 Using mice 
expressing murine )LEȖ390-396A fibrinogen, we previously detected delayed FXIII activation and 
fibrin crosslinking in plasma.4 To directly determine the contribution of fibrin(ogen) residues 
Ȗ390-396 to these functions, we now assessed the ability of human )LEȖ390-396A fibrin(ogen) to 
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support FXIII-A2B2 activation in a purified system. Compared to reactions with human Ȗ$Ȗ$ 
fibrin(ogen), reactions with )LEȖ390-396A fibrin(ogen) showed 2.7-fold slower release of the FXIII 
activation peptide (2.35 ± 0.46% vs. 0.87 ± 0.20% FXIII-Aމ/minute, respectively, P<0.02, Figure 
2A-C), and was similar to that observed in the absence of fibrinogen (0.96 ± 0.16% FXIII-
Aމ/minute, P=0.8, Figure 2A-C).  
 The rate of fibrin formation was similar IRUȖ$Ȗ$ and )LEȖ390-396A (Figure 2D and data not 
shown). However, the rate of fibrin crosslinking was slower for FibȖ390-396A. Specifically, Ȗ-Ȗ
dimer formation was 2.5-fold slower (6.7 ± 1.5 versus 17.0 ± 1.3% Ȗ-Ȗ/minute, for )LEȖ390-396A 
versus Ȗ$Ȗ$UHVSHFWLYHO\, Figure 2D-F). The delays in both FXIII-A2B2 activation and 
crosslinking activity are consistent with a lack of binding of zymogen FXIII-A2B2 to )LEȖ390-396A 
fibrinogen. 
 
The ability of fibrin(ogen) residues Ȗ-396 to accelerate FXIII activation is FXIII-B 
subunit-dependent. Souri et al. previously suggested the acceleratory effect of fibrin(ogen) on 
FXIII-A2B2 activation is FXIII-B subunit-dependent.12 We therefore also measured activation of 
FXIII-A2 (rFXIII-A2) in the absence of FXIII-B2 and compared these rates in the presence of 
Ȗ$Ȗ$ and )LEȖ390-396A fibrin(ogen). Compared to activation of FXIII-A2B2, activation of rFXIII-
A2 was slower (Figure 2A-C and Figure 3A-C, P<0.02), consistent with a critical role for the 
FXIII-B subunits in this reaction. Interestingly, however, in contrast to that seen with FXIII-
A2B2, activation of rFXIII-A2 was similar in the presence of Ȗ$Ȗ$ and )LEȖ390-396A fibrin(ogen) 
(0.60 ± 0.06 vs. 0.46 ± 0.06% FXIII-Aމ/minute, respectively, Figure 3A-C). Moreover, in the 
presence of rFXIII-A2, the fRUPDWLRQUDWHRIȖ-ȖGLPHUVZDVPRUHVLPLODUIRUȖ$Ȗ$ and )LEȖ390-
396A
 (15.6 ± 0.5 versus 12.6 ± 0.5% Ȗ-Ȗminute, respectively, Figure 3D-F), relative to reactions 
in the presence of FXIII-A2B2. These findings show )LEȖ390-396A can be crosslinked, indicating 
the delayed crosslinking seen with FXIII-A2B2 (Figure 2D-F) was not due to a substantial 
disruption of structure in this region. Rather, these data attribute the delay seen with FXIII-A2B2 
(Figure 2D-F) to decreased interaction between fibrin(ogen) residues Ȗ390-396 and the FXIII-B 
subunit. Together, these data suggest the presence of fibrin(ogen) residues Ȗ390-396 accelerate 
FXIII activation, and do so in a FXIII-B subunit-dependent mechanism. 
 
The FXIII-B subunit binds fibrinogen residues Ȗ-396. We then directly tested the 
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hypothesis that FXIII binding WRILEULQRJHQUHVLGXHVȖ-396 is mediated by the B subunits 
using both precipitation and SPR assays. First, we precipitated UHFRPELQDQWȖ$Ȗ$ or )LEȖ390-396A 
fibrinogen in the presence of rFXIII-A2, rFXIII-B2, or rFXIII-A2 plus rFXIII-B2. rFXIII-A2 did 
not co-precipitate with either Ȗ$Ȗ$ or )LEȖ390-396A fibrinogen (Figure 4A, B). However, rFXIII-
B2 readily co-precipitated with Ȗ$Ȗ$ fibrinogen (Figure 4A), but not )LEȖ390-396A fibrinogen 
(Figure 4B). Addition of rFXIII-B2 to rFXIII-A2 promoted co-precipitation of rFXIII-A2 with 
Ȗ$Ȗ$ fibrinogen (Figure 4A), likely through the formation of rFXIII-A2B2 heterotetramers. 
Conversely, rFXIII-B2 did not promote rFXIII-A2 co-precipitation with )LEȖ390-396A (Figure 4B). 
Experiments using purified, plasma-derived Ȗ$Ȗ$Seak 1) fibrinogen fully recapitulated 
findings with UHFRPELQDQWȖ$Ȗ$GDWDQRWVKRZQ 
 Second, we examined binding of the fibrinogen variants to surface-bound rFXIII-B2. These 
data revealed that Ȗ$Ȗ$ bound rFXIII-B2 with similar affinity as seen with FXIII-A2B2 (Table 
1, Supplemental Figure 2)ȖމȖމDQG$ĮILEULQRJHQVDOVRERXQGU);,,,-B2 (Table 1, 
Supplemental Figure 2), indicating both that the binding motif for FXIII-B2 is present on each of 
these fibrinogen molecules and that the presence of FXIII-A2 does not enhance FXIII-B2 binding 
to fibrinogen. These data also confirm that rFXIII-B2 co-precipitation with fibrinogen in the 
previous experiments was not due to the presence of glycine. Notably, however, we were unable 
to detect binding of )LEȖ390-396A fibrinogen to rFXIII-B2 (Table 1, Supplemental Figure 2). 
Collectively, these co-precipitation and SPR data indicate that the FXIII-B subunit(s) of FXIII-
A2B2 mediate binding to fibrinogen UHVLGXHVȖ-396. 
 
Excess FXIII-B2 in plasma circulates bound to fibrinogen. FXIII-B2 is present in ~2-fold 
molar excess over FXIII-A2 in plasma and is thought to circulate as free (unbound) FXIII-B2 
homodimer.2,3 However, the co-precipitation and SPR data indicating FXIII-B2 can bind 
fibrinogen in the absence of FXIII-A2 (Figure 4A, Table 1) raise the interesting possibility that 
³IUHH´);,,,-B2 in plasma actually circulates bound to fibrinogen. Indeed, given the measured 
affinity of FXIII-B2 to fibrinogen (0.4 nM, Table 1) and the estimated plasma concentration of 
³free´ FXIII-B2 (~43-62 nM)2,3, greater than 99% of circulating FXIII-B2 should be bound to 
fibrinogen. Therefore, to determine whether FXIII-B2 circulates with fibrinogen in plasma, we 
precipitated fibrinogen from plasma from FXIII-A2-sufficient (F13a+/+) and FXIII-A2-deficient 
(F13a+/- and F13a -/-) mice4,16 and used SDS-PAGE and Western blotting to detect FXIII-B in the 
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precipitate. Consistent with previous observations29, there was a FXIII-A subunit dose effect on 
the total amount of FXIII-B present in the initial plasma sample (Figure 5A), suggesting FXIII-
A2 influences the circulating level of FXIII-B2. Regardless, Figure 5A shows that FXIII-B2 co-
precipitated with fibrinogen from FXIII-A-deficient plasma. Experiments using human FXIII-A-
deficient plasma fully recapitulated findings with FXIII-A-deficient mouse plasma (Figure 5B). 
To test the specificity of the precipitation protocol, we subjected afibrinogenemic mouse plasma 
to glycine precipitation. As expected, no fibrinogen was precipitated (Figure 5C). Importantly, 
glycine did not precipitate FXIII-B2 from afibrinogenemic mouse plasma (Figure 5C), indicating 
that FXIII precipitation in these experiments is fibrinogen-dependent. Thus, these data suggest 
excess FXIII-B2 in plasma does not circulate LQD³IUHH´VWDWHEXWLQVWHDGFLUFXODWHV bound to 
fibrinogen. 
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DISCUSSION 
 The observation that FXIII-A2B2 circulates in complex with fibrinogen is well-established; 
however, the motifs on fibrinogen and FXIII-A2B2 that mediate this interaction have been 
controversial. Our study that integrates both solid- and solution-phase binding experiments and 
functional assays reveals critical components of both fibrinogen and FXIII-A2B2 necessary for 
binding. First, our data indicate that the primary binding site for zymogen FXIII-A2B2 on human 
fibrinogen is not found in the alternatively-VSOLFHGȖމ-H[WHQVLRQRUWKHĮ&UHJLRQEXWLQVWHDGOLHV
ZLWKLQȖ-chain residues 390-396. Together with data from mice4, this finding suggests these 
highly-conserved fibrinogen residues mediate this interaction in multiple species. Second, we 
showed that FXIII-A2B2 binds fibrinogen residues Ȗ-396 via the FXIII-B subunits. These data 
support previous studies suggesting an interaction between the FXIII-B subunit and 
fibrinogen8,12, and extend these findings by defining the FXIII-B binding motif on fibrinogen. 
Third, we showed that FXIII-B2 can bind fibrinogen in the absence of FXIII-A2. This intriguing 
finding suggests ³IUHH´);,,,-B2 in plasma actually circulates bound to fibrinogen, and has 
important implications for understanding assembly of the fibrinogen/FXIII-A2B2 complex in 
both physiologic and therapeutic situations.  
 Our finding that fibrinogen residues Ȗ390-396 support FXIII-A2B2 binding are consistent 
with several prior studies implicating the D-domain30, residues C-terminal to residue Lys356 of 
WKHȖ-chain12DQGUHVLGXHVȖ-396 of murine fibrinogen4 in this interaction. However, our 
findings are discordant with studies implicating the alternatively-spliced Ȗމ-chain8,9 as the 
primary mediator of this interaction. The reasons for this discord may relate to differences in the 
assay systems used. For example, although experiments using anion exchange chromatography 
suggested FXIII-A2B2 elutes in the same fraction as ȖA/Ȗމ, this study did not directly compare 
binding of FXIII-A2B2 to these fibrinogen variants.8 In contrast we tested this interaction by both 
co-precipitation and direct binding assays that enabled us to maintain fibrinogen in solution 
during the binding events. This assay design may be particularly important because the same 
residues we have implicated in FXIII-A2B2 binding have previously been shown to support 
ILEULQRJHQELQGLQJWRWKH&'EĮM) subunit of CD11b/CD18 (Mac-1) integrin present on 
monocytes, macrophages, and neutrophils.21,31 The observation from those studies that CD11b 
ELQGVWRUHVLGXHVȖ-396 in insoluble fibrin and adherent fibrin(ogen), but not soluble 
fibrinogen, has led to the hypothesis that fibrin formation or fibrinogen adherence to a surface 
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induces structural changes within these residues. Thus, previous experimental designs that used 
surface (or resin)-bound fibrin(ogen) or fibrin6,8,26,32,33 may not have recapitulated the 
conformation of residues Ȗ-396 that would bind zymogen FXIII when fibrinogen is in 
solution. This possibility is also interesting when considering the role of the nearby fibrin(ogen) 
ȖމH[WHQVLRQUHVLGXHV-427) in FXIII-A2B2 binding. If residues in the Ȗމ-extension influence 
structure within UHVLGXHVȖ-396, data from assays using surface- or resin-bound fibrin(ogen) 
or fibrin may have indicated the alternatively-splLFHGȖމ-chain has different affinity for FXIII-
A2B2. Similarly, ultracentrifugation experiments with ȖA/Ȗމ fibrinogen9 may have been 
confounded by the presence of gel-like fibrin(ogen) dimers34,35. Thus, these conditions may have 
led to the conclusion that the zymogen ELQGLQJPRWLILVFRQWDLQHGZLWKLQWKHȖމ-extension. 
 More recent findings that FXIII-A2B2 ELQGVWRDSHSWLGHGHULYHGIURPWKHILEULQRJHQĮ&
GRPDLQUHVLGXHVĮ-425) suggested FXIII-A2B2 binds to the fibrinogen ĮC region.11 In that 
study11 it was not possible to distinguish the relative contributions of the ĮC region versus the D-
region to this interaction in full-length fibrinogen. Our SPR data suggesting $ĮILEULQRJHQ
has weaker binding to FXIII-A2B2 than does ȖAȖA fibrinogen suggests some FXIII-binding 
character is also GHULYHGIURPWKHĮ&GRPDLQ. Future studies using variant fibrinogens with 
combined mutations in the Ȗ- and Į-chains may resolve the relative contribution of the ĮC region 
in this interaction.  
 The high degree of inter-VSHFLHVKRPRORJ\ZLWKLQILEULQRJHQUHVLGXHVȖ-396 has 
traditionally been attributed to their other essential function in supporting fibrin(ogen) binding to 
CD11b.21,31 Interestingly, the earliest FXIII-fibrinogen system36 DQGWKHĮM I-domain that binds 
fibrin37,38 appeared together with the rise of vertebrates over 400 million years ago. No 
homozygous mutations have been identified in this region, emphasizing the physiologic 
importance of this fibrin(ogen) sequence. Therefore, the high homology in this region may result 
from strong evolutionary pressure to maintain both of these functions. Although the same 
fibrinogen residues mediate binding to both FXIII-A2B2 and CD11b, it is unlikely that these 
binding events compete. First, there is a vast excess of fibrinogen relative to FXIII-A2B2. 
Second, FXIII-A2B2 circulates with soluble fibrinogen6, whereas CD11b binds insoluble fibrin39. 
Thus, these interactions likely occur in distinct physiologic settings. 
 Based on our and published findings, we propose the following model (Figure 6). FXIII-
A2B2 circulates bound to fibrinogen at a site comprised of residues Ȗ390-396 and supported by 
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the Į&UHgion.11 During coagulation, fibrinogen transports FXIII-A2B2 into the nascent clot via 
its interaction with the FXIII-B subunits. As fibrin polymerizes, FXIII-A2B2 bound to the D-
domain of one fibrin monomer contacts thrombin bound to the E-domain of another fibrin 
monomer at the D:E:D interface.40 Formation of this complex promotes FXIII activation peptide 
cleavage and release from the FXIII-A subunits22-28,40, followed by dissociation of the FXIII-B 
subunits from the FXIII-A subunits12,22. These sequential steps yield fully-activated FXIII-A2*. 
Generation of FXIII-A2* at residues Ȗ-396 conveniently localizes FXIIIa near WKHȖ-chain 
crosslinking sites UHVLGXHVȖ4DQGȖ., which are the first fibrin residues to undergo 
crosslinking.20,41-43 This Ȗ-chain crosslinking also promotes FXIII-B2 dissociation from the fibrin 
clot.12 The FXIII-A2* interaction with Į& residue E39611,44,45 then facilitates the translocation of 
its active site to the ILEULQĮ-chain, where it catalyzes the formation of crosslinks between fibrin 
Į-chains and between Į-chains and other plasma proteins. Formation of these crosslinks is 
critical for the ability of FXIII(a) to promote resistance of clots to biomechanical and 
biochemical disruption. Moreover, we recently showed that the spatio-temporal regulation of 
FXIII activation kinetics during coagulation is also critical for determining red blood cell 
retention in contracted clots.4 Thus, this model reconciles data from studies on the binding, 
activation, and activity of FXIII and reveals the importance of the FXIII-B subunits in 
fibrinogen/FXIII-A2B2 interactions, in FXIII-A2B2 activation, and consequently, in fibrin 
crosslinking and clot composition and stability. Although we did not identify the specific FXIII-
B residues that mediate this interaction, previous studies have implicated sushi domains 1 and/or 
10 in this interaction.12 Further studies are ongoing to localize the FXIII-B residues that support 
binding to fibrinogen residues Ȗ390-396. 
 A major finding from this work is the observation that FXIII-B2 can bind fibrinogen in the 
absence of FXIII-A2. Notably, the tight affinity of FXIII-B2 binding to fibrinogen, together with 
the plasma concentrations of FXIII-B2 and fibrinogen, suggests essentially all FXIII-B2 in 
plasma is bound to fibrinogen. This observation appears to FRQWUDGLFWWKHWHQHWWKDW³IUHH B´ 
circulates in plasma.3 However, FXIII-B2 used in the previous report3 was prepared by 
ammonium sulfate precipitation and heat denaturation to specifically remove fibrinogen. Thus, 
that study was not designed to characterize FXIII binding to other plasma proteinsDQG³IUHH%´
was likely RQO\PHDQWWRLPSO\³QRWERXQGWR);,,,-A2.´ Description of this material has been 
(incorrectly) interpreted more broadly since that time. Since both FXIII-B2 and fibrinogen are 
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synthesized by hepatocytes, these proteins may associate during or immediately following their 
secretion. Subsequent association of the FXIII-A2 subunits, which are synthesized by cells of 
bone marrow origin, with the fibrinogen/FXIII-B2 complex would then result in formation of the 
complete fibrinogen/FXIII-A2B2 complex. Consequently, our data that suggest FXIII-B2 
circulates bound to fibrinogen may reveal part of a step-wise mechanism that leads to production 
of fibrinogen/FXIII-A2B2 complexes. In addition, these data may have important implications for 
understanding the mechanism of action of therapeutic rFXIII-A2 infusion for FXIII-A-
deficiency. Binding of infused rFXIII-A2 to fibrinogen-bound FXIII-B2 YHUVXV³IUHH´);,,,-B2) 
ensures that rFXIII-A2 will become incorporated into a functional, fibrinogen-bound complex, 
which is crucial for normal FXIII activation and function. 
 Our study has potentiaOOLPLWDWLRQV)LUVWWKHORVVRI);,,,ELQGLQJWRWKH)LEȖ390-396A mutant 
may reflect GLVUXSWHGVWUXFWXUHZLWKLQWKHȖ-domain. However, this possibility seems unlikely 
because crystallographic studies suggest this region is inherently disordered even in the native 
molecule.46-48 Moreover, although the pattern of fibrin crosslinking is subtly altered in both 
mouse4 and KXPDQ)LEȖ390-396A clots, both murine4,21 and human )LEȖ390-396A can be fully 
crosslinked at the canonical residues located immediately C-WHUPLQDOWRȖ-Ȗ4
DQGȖ.. Thus, mutations within these residues do not appear to catastrophically alter 
structure within this domain. Second, the protocol used to precipitate fibrinogen may also 
promote FXIII precipitation and/or FXIII interaction with fibrinogen, and we and others8 have 
observed spontaneous precipitation of isolated FXIII-B subunits in certain experiments. 
However, glycine did not precipitate FXIII from afibrinogenemic plasma or in the presence of 
non-binding )LEȖ390-396A fibrinogen. Moreover, data from the precipitation experiments were 
supported by both SPR analyses and functional FXIII activation assays performed in the absence 
of glycine.  
 In summary, our data expose critical molecular interactions mediating FXIII binding to 
fibrinogen. Identification of these motifs advances our understanding of this interaction in both 
physiologic and pathophysiologic situations. 
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TABLE 
 
Immobilized 
Ligand Analyte 
 
N 
Equilibrium dissociation constant 
(KD), nM 
FXIII-A2B2 Ȗ$Ȗ$ 6 3.8 ± 2.4 
 ȖމȖމ 6 10.4 ± 11.1 
  $Į 3 71.0 ± 16.2 
  )LEȖ390-396A 6 No Binding 
  
 
 
 
rFXIII-B2 Ȗ$Ȗ$ 4 0.4 ± 0.3 
 ȖމȖމ 6 53.0 ± 75.1 
  $Į 4 58.6 ± 26.5 
  )LEȖ390-396A 6 No Binding 
  
Table 1. SPR analysis of fibrinogen variant binding to immobilized FXIII-A2B2 and 
rFXIII-B2. Equilibrium dissociation constant values are mean ± SD for the number of 
experiments indicated.  
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FIGURES 
Figure 1. )LEULQRJHQUHVLGXHVȖ-396 are necessary for FXIII-A2B2 binding. Recombinant 
KXPDQILEULQRJHQYDULDQWVȖ$Ȗ$ȖމȖމ$ĮDQG)LEȖ390-396A) were mixed with FXIII-A2B2 
(1 mg/mL and 20 µg/mL, final, respectively) and precipitated with glycine. (A) Representative 
Western blots for fibrinogen (Fgn), FXIII-A, and FXIII-B in the initial sample (I), pellet (P), or 
supernatant (S). Note that P and S samples were taken after the addition of glycine and are 
therefore subject to a dilution effect relative to the I sample. (B) Quantitation of all blots, 
indicating percent of FXIII-A or FXIII-B in the pellet, relative to total FXIII in the pellet and 
supernatant. Bars are means ± SEM, n=3. 
 
Figure 2. Fibrin(ogen) UHVLGXHVȖ-396 mediate the acceleratory effect of fibrin(ogen) on 
FXIII-A2B2 activation. FXIII-A2B2 (20 µg/mL [60 nM], final) was mixed with recombinant 
ILEULQRJHQVȖ$Ȗ$ or )LEȖ390-396A, 150 µg/mL, final) or buffer (No Fgn). Reactions were 
triggered by addition of thrombin (2 nM, final) and CaCl2 (10 mM, final), quenched at the 
indicated time points, and analyzed by SDS-PAGE with Western blotting and densitometry. 
Activation peptide cleavage was detected using anti-FXIII-A antibody. Fibrin crosslinking was 
detected using anti-fibrinogen antibody. (A) Representative Western blots and (B) quantitation of 
FXIII-A2B2 activation over time from all blots. (C) Maximal rates of FXIII-A2B2 activation 
calculated from panel B. (D) Representative Western blots of fibrin crosslinking, and 
quantitation of (EȖ-ȖGLPHUformation and (F) Ȗ-ȖGLPHU formation rate. Data are means ± SEM, 
n=3-6 replicates per time point. 
 
Figure 3. Fibrin(ogen) UHVLGXHVȖ-396 do not accelerate FXIII-A2 activation. 
Recombinant FXIII-A2 JP/>Q0@ILQDOZDVPL[HGZLWKȖ$Ȗ$ or )LEȖ390-396A 
fibrinogen (150 µg/mL, final). Reactions were triggered by addition of thrombin (2 nM, final) 
and CaCl2 (10 mM, final), quenched at the indicated time points, and analyzed by SDS-PAGE 
with Western blotting and densitometry. Activation peptide cleavage was detected using anti-
FXIII-A antibody. Fibrin crosslinking was detected using anti-fibrinogen antibody. (A) 
Representative Western blots and (B) quantitation of rFXIII-A2 activation over time from all 
blots. (C) Maximal rates of rFXIII-A2 activation were calculated from quantified Western blots. 
(D) Representative Western blots of fibrin crosslinking and quantification of (EȖ-ȖGLPHU
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formation and (F) formation rate. Data are means ± SEM, n=4 experiments. 
 
Figure 4. FXIII-A2B2 binds fibrLQRJHQUHVLGXHVȖ-396 via the FXIII-B subunits. 
Recombinant FXIII-A2 (10 µg/mL [60 nM], final), rFXIII-B2 (10 µg/mL [62 nM], final), or both, 
were mixed with (A) Ȗ$Ȗ$ or (B) )LEȖ390-396A fibrinogen (1 mg/mL, final) and precipitated with 
glycine. (A-B) Representative Western blots for fibrinogen (Fgn), FXIII-A, and FXIII-B in the 
initial sample (I), pellet (P), or supernatant (S). Note that P and S samples were taken after the 
addition of glycine and are therefore subject to a dilution effect relative to the I sample. Blots are 
representative of n=3 experiments. 
 
Figure 5. In the absence of FXIII-A2, FXIII-B2 co-precipitates with plasma fibrinogen. 
Fibrinogen was precipitated from (A) F13a+/+, F13a+/-, or F13a-/- mouse plasma, (B) FXIII-
depleted human plasma, or (C) afibrinogenemic mouse plasma using glycine. Panels show 
representative Western blots for fibrinogen (Fgn), FXIII-A, and FXIII-B in the initial plasma (I), 
pellet (P), or supernatant (S) under reducing (Fgn) or non-reducing (FXIII-A, FXIII-B) 
conditions. Note in panel ASODVPDDOEXPLQLQ,DQG6VDPSOHVFDXVHVWKH$Į-chain to migrate 
faster than in the P samples. Blots are representative of n=3 experiments with mouse plasmas, 
and n=2 experiments with human plasma. 
 
Figure 6. FXIII-A2B2 binding to fibrinogen residues Ȗ-396 promotes FXIII-A2B2 
activation and activity. (A) )LEULQRJHQLVFRPSULVHGRIWZR$Į- (medium gra\WZR%ȕ- (dark 
JUD\DQGWZRȖ-chains (light gray) arranged in a trinodular structure with two distal D-domains 
and a central E-GRPDLQ7KH$Į-chains have a C-WHUPLQDOGRPDLQĮ&WKDWH[WHQGVEH\RQGWKH
D-domain. FXIII-A2B2 FLUFXODWHVERXQGWRILEULQRJHQȖ-chain residues 390-396 via the FXIII-B 
subunits. (B) Once coagulation is initiated, thrombin interacts with the fibrinogen E-domain and 
FOHDYHVILEULQRSHSWLGHV$IURPWKH$Į-chains. As fibrin monomers polymerize, FXIII-A2B2 
DVVRFLDWHGZLWKȖ-396 is brought into contact with thrombin at the D:E:D interface to form a 
ternary complex.40 This complex facilitates thrombin-mediated activation peptide cleavage from 
the FXIII-A subunits.22-28,40, Following activation peptide cleavage, fibrin promotes the calcium-
mediated FXIII-B subunit dissociation from the FXIII-A subunits to yield FXIIIa.12,22 (C) FXIIIa 
then crosslinks (black line) the nearby Ȗ-chains yielding Ȗ-Ȗ dimers.20  This Ȗ-chain crosslinking 
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also promotes dissociation of FXIII-B2 from the fibrin clot.12 (D) FXIIIa translocates from the Ȗ-
chain to the ĮC region, binding at or near Į-chain residue E39611,44,45, and catalyzes the 
formation of crosslinks between fibrin Į-chains and between fibrin and other plasma proteins. 
 
